After announcing this summer that i...

After announcing this summer that it would delay shipments if its influenza vaccine befitting to contamination of some parts Chiron announced in October that it would not serve instead of any of the expected 50 million doses of Fluvirin this flu season. In unfolding exhibitions that have caused an uproar through price gouging and become a political football in the US presidential elections, UK regulators temporarily suspended Chiron's license to manufacture Fluvirin at its Liverpool, UK facility, citing a failure to comply with profitable manufacturing practices (GMPs).

The three-month suspension